​

Legend Biotech (LEGN) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

LEGN Stock Forecast

Legend Biotech stock forecast is as follows: an average price target of $89.60 (represents a 163.37% upside from LEGN’s last price of $34.02) and a rating consensus of 'Buy', based on 14 wall street analysts offering a 1-year stock forecast.

LEGN Price Target

The average price target for Legend Biotech (LEGN) is $89.60 based on 1-year price targets from 14 Wall Street analysts in the past 3 months, with a price target range of $94.00 to $83.00. This represents a potential 163.37% upside from LEGN's last price of $34.02.

LEGN Analyst Ratings

Buy

According to 14 Wall Street analysts, Legend Biotech's rating consensus is 'Buy'. The analyst rating breakdown for LEGN stock is 0 'Strong Buy' (0.00%), 13 'Buy' (92.86%), 1 'Hold' (7.14%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Legend Biotech Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024Rick BienkowskiCantor Fitzgerald$83.00$55.9048.48%143.97%
Oct 15, 2024Justin ZelinBTIG$91.00$44.91102.63%167.49%
Oct 15, 2024Gena WangJohnson Rice$94.00$45.24107.76%176.31%
Oct 15, 2024Gena WangBarclays$94.00$44.91109.31%176.31%
Oct 08, 2024Qize DingRedburn Partners$86.00$49.5873.46%152.79%
Jun 17, 2024Edward TenthoffPiper Sandler$90.00$42.00114.29%164.55%
Jun 17, 2024Asthika GoonewardeneTruist Financial$88.00$42.45107.30%158.67%
May 23, 2024James ShinDeutsche Bank$60.00$40.0449.85%76.37%
May 17, 2024Matthew HarrisonMorgan Stanley$82.00$46.3776.84%141.03%
May 14, 2024Leonid TimashevRBC Capital$86.00$42.97100.14%152.79%
Apr 17, 2024George FarmerScotiabank$65.00$50.1229.69%91.06%
Apr 03, 2024Rick BienkowskiCantor Fitzgerald$82.00$56.4345.31%141.03%
Mar 14, 2024Kostas BiliourisBMO Capital$90.00$66.1136.14%164.55%
Dec 06, 2022UBS$66.00$50.9929.44%94.00%

The latest Legend Biotech stock forecast, released on Nov 13, 2024 by Rick Bienkowski from Cantor Fitzgerald, set a price target of $83.00, which represents a 48.48% increase from the stock price at the time of the forecast ($55.90), and a 143.97% increase from LEGN last price ($34.02).

Legend Biotech Price Target by Period

1M3M12M
# Anlaysts-513
Avg Price Target-$89.60$83.92
Last Closing Price$34.02$34.02$34.02
Upside/Downside-100.00%163.37%146.68%

In the current month, the average price target of Legend Biotech stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Legend Biotech's last price of $34.02. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 13, 2024Cantor FitzgeraldOverweightOverweightHold
Oct 16, 2024BMO CapitalOutperformOutperformHold
Oct 16, 2024Johnson RiceBuyBuyHold
Oct 15, 2024BTIGBuyBuyHold
Oct 15, 2024Johnson RiceOverweightOverweightHold
Oct 15, 2024BarclaysOverweightOverweightHold
Oct 11, 2024Cowen & Co.BuyBuyHold
Oct 04, 2024H.C. WainwrightBuyBuyHold
Sep 27, 2024RBC CapitalUnderperformUnderperformHold
Sep 27, 2024ScotiabankBuyBuyHold
Aug 28, 2024H.C. WainwrightBuyBuyHold
Aug 12, 2024ScotiabankBuyBuyHold
Aug 12, 2024RBC CapitalUnderperformUnderperformHold
Aug 12, 2024ScotiabankOutperformOutperformHold
Jul 18, 2024ScotiabankOutperformOutperformHold
Jul 15, 2024ScotiabankBuyBuyHold
Jul 15, 2024RBC CapitalUnderperformUnderperformHold
Jun 21, 2024ScotiabankBuyBuyHold
Jun 21, 2024RBC CapitalUnderperformUnderperformHold
Jun 21, 2024RBC CapitalOutperformOutperformHold
Jun 17, 2024Piper SandlerOverweightOverweightHold
Jun 04, 2024ScotiabankUnderperformUnderperformHold
Jun 04, 2024UBSBuyBuyHold
May 31, 2024CitigroupBuyBuyHold
May 23, 2024Deutsche BankBuyInitialise
May 17, 2024Morgan StanleyOverweightOverweightHold
May 14, 2024RBC CapitalOutperformOutperformHold
May 14, 2024ScotiabankUnderperformUnderperformHold
May 14, 2024UBSSector OutperformSector OutperformHold
May 14, 2024H.C. WainwrightBuyBuyHold
Apr 17, 2024BMO CapitalOutperformOutperformHold
Apr 17, 2024UBSSector OutperformSector OutperformHold
Apr 17, 2024ScotiabankUnderperformUnderperformHold
Apr 17, 2024ScotiabankSector PerformOutperformUpgrade
Apr 16, 2024Johnson RiceBuyBuyHold
Apr 03, 2024Cantor FitzgeraldOverweightInitialise
Apr 01, 2024UBSBuyBuyHold
Mar 07, 2024ScotiabankSector PerformSector PerformHold
Mar 07, 2024RBC CapitalUnderperformUnderperformHold
Oct 18, 2023Johnson RiceBuyBuyHold
May 25, 2023William BlairMarket PerformInitialise
Apr 19, 2023BTIGBuyBuyHold
Dec 06, 2022UBSBuyInitialise
Jun 17, 2022BMO CapitalOutperformInitialise

Legend Biotech's last stock rating was published by Cantor Fitzgerald on Nov 13, 2024. The company gave LEGN a "Overweight" rating, the same as its previous rate.

Legend Biotech Financial Forecast

Legend Biotech Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
Revenue---------------$36.34M$25.21M-$11.97M$40.83M$38.99M$16.88M$20.23M$13.68M$40.78M$11.75M$11.60M
Avg Forecast$474.50M$432.20M$393.67M$358.58M$305.33M$263.87M$253.43M$197.15M$178.98M$143.91M$125.25M$143.24M$94.08M$97.25M$56.64M$42.18M$32.34M$32.34M$33.62M$25.00M$14.27M$7.83M$9.13M$6.50M$13.00M$13.00M$13.00M
High Forecast$538.03M$490.07M$446.38M$406.59M$346.22M$299.20M$287.36M$212.73M$197.69M$147.90M$125.25M$143.24M$106.19M$110.28M$64.22M$47.82M$36.67M$32.34M$33.62M$25.00M$14.27M$7.83M$9.13M$6.50M$13.00M$13.00M$13.00M
Low Forecast$428.34M$390.15M$355.37M$323.69M$275.63M$238.20M$228.77M$184.06M$158.28M$139.93M$125.25M$143.24M$81.55M$87.79M$51.13M$38.07M$29.20M$32.34M$33.62M$25.00M$14.27M$7.83M$9.13M$6.50M$13.00M$13.00M$13.00M
# Analysts222211149434756322223456633
Surprise %---------------0.86%0.78%-0.36%1.63%2.73%2.16%2.22%2.10%3.14%0.90%0.89%

Legend Biotech's average Quarter revenue forecast for Jun 23 based on 6 analysts is $56.64M, with a low forecast of $51.13M, and a high forecast of $64.22M. LEGN's average Quarter revenue forecast represents a 55.87% increase compared to the company's last Quarter revenue of $36.34M (Mar 23).

Legend Biotech EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211149434756322223456633
EBITDA---------------$-126.86M$317.86M-$-125.53M$-71.07M$-87.73M$-124.54M$-91.53M$-80.86M$-61.73M$-66.96M$-134.79M
Avg Forecast$-474.50M$-432.20M$-393.67M$-358.58M$-305.33M$-263.87M$-253.43M$-197.15M$-178.98M$-143.91M$-125.25M$-143.24M$-94.08M$-97.25M$-56.64M$-42.18M$-32.34M$-32.34M$-33.62M$-25.00M$-14.27M$-7.83M$-9.13M$-92.41M$-13.00M$-13.00M$-345.26M
High Forecast$-428.34M$-390.15M$-355.37M$-323.69M$-275.63M$-238.20M$-228.77M$-184.06M$-158.28M$-139.93M$-125.25M$-143.24M$-81.55M$-87.79M$-51.13M$-38.07M$-29.20M$-32.34M$-33.62M$-25.00M$-14.27M$-7.83M$-9.13M$-73.93M$-13.00M$-13.00M$-276.21M
Low Forecast$-538.03M$-490.07M$-446.38M$-406.59M$-346.22M$-299.20M$-287.36M$-212.73M$-197.69M$-147.90M$-125.25M$-143.24M$-106.19M$-110.28M$-64.22M$-47.82M$-36.67M$-32.34M$-33.62M$-25.00M$-14.27M$-7.83M$-9.13M$-110.90M$-13.00M$-13.00M$-414.32M
Surprise %---------------3.01%-9.83%-3.73%2.84%6.15%15.90%10.02%0.88%4.75%5.15%0.39%

3 analysts predict LEGN's average Quarter EBITDA for Mar 23 to be $-42.18M, with a high of $-38.07M and a low of $-47.82M. This is -113.27% lower than Legend Biotech's previous annual EBITDA (Dec 22) of $317.86M.

Legend Biotech Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211149434756322223456633
Net Income---------------$-112.10M$319.93M-$-193.23M$-42.08M$-84.62M$-121.25M$-91.58M$-82.21M$-57.83M$-66.55M$-213.63M
Avg Forecast$77.83M$63.40M$43.70M$26.79M$-6.34M$-18.60M$-23.01M$-34.42M$-44.67M$-60.21M$-52.49M$-35.33M$-64.93M$-56.63M$-65.91M$-76.23M$-68.17M$-68.17M$-56.64M$-65.43M$-62.41M$-75.89M$-61.17M$-92.46M$-51.74M$-56.00M$-345.49M
High Forecast$91.37M$74.44M$51.30M$31.45M$-5.54M$-16.24M$-20.10M$-20.43M$-18.73M$-52.60M$-45.85M$-30.86M$-38.96M$-49.47M$-57.57M$-66.59M$-59.55M$-68.17M$-56.64M$-65.43M$-62.41M$-75.89M$-61.17M$-73.96M$-51.74M$-56.00M$-276.39M
Low Forecast$67.98M$55.38M$38.17M$23.40M$-7.45M$-21.83M$-27.01M$-41.94M$-86.47M$-70.69M$-61.62M$-41.48M$-79.77M$-66.48M$-77.38M$-89.50M$-80.04M$-68.17M$-56.64M$-65.43M$-62.41M$-75.89M$-61.17M$-110.95M$-51.74M$-56.00M$-414.59M
Surprise %---------------1.47%-4.69%-3.41%0.64%1.36%1.60%1.50%0.89%1.12%1.19%0.62%

Legend Biotech's average Quarter net income forecast for Mar 23 is $-76.23M, with a range of $-89.50M to $-66.59M. LEGN's average Quarter net income forecast represents a -123.83% decrease compared to the company's last Quarter net income of $319.93M (Dec 22).

Legend Biotech SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211149434756322223456633
SG&A---------------$40.16M$-242.82M-$45.49M$33.96M$69.95M$31.34M$26.03M$22.16M$33.35M$15.32M$14.06M
Avg Forecast$510.86M$465.32M$423.84M$386.06M$328.73M$284.09M$272.85M$212.25M$192.69M$154.94M$134.85M$154.22M$101.29M$104.71M$60.98M$45.41M$34.82M$34.36M$35.71M$26.56M$15.16M$8.32M$9.70M$6.90M$13.81M$13.81M$13.81M
High Forecast$579.26M$527.62M$480.59M$437.75M$372.75M$322.13M$309.38M$229.03M$212.84M$159.23M$134.85M$154.22M$114.33M$118.73M$69.14M$51.49M$39.48M$34.36M$35.71M$26.56M$15.16M$8.32M$9.70M$6.90M$13.81M$13.81M$13.81M
Low Forecast$461.16M$420.05M$382.61M$348.50M$296.75M$256.45M$246.30M$198.16M$170.40M$150.65M$134.85M$154.22M$87.80M$94.52M$55.04M$40.99M$31.43M$34.36M$35.71M$26.56M$15.16M$8.32M$9.70M$6.90M$13.81M$13.81M$13.81M
Surprise %---------------0.88%-6.97%-1.27%1.28%4.61%3.77%2.68%3.21%2.42%1.11%1.02%

Legend Biotech's average Quarter SG&A projection for Jun 23 is $60.98M, based on 6 Wall Street analysts, with a range of $55.04M to $69.14M. The forecast indicates a 51.84% rise compared to LEGN last annual SG&A of $40.16M (Mar 23).

Legend Biotech EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20
# Analysts222211149434756322223456633
EPS---------------$-0.68$2.01-$-1.25$-0.27$-0.58$-0.84$-0.66$-0.62$-0.44$-0.50$-1.98
Avg Forecast$0.43$0.35$0.24$0.15$-0.03$-0.10$-0.13$-0.19$-0.24$-0.33$-0.29$-0.19$-0.36$-0.31$-0.36$-0.42$-0.37$-0.37$-0.31$-0.36$-0.34$-0.42$-0.34$-0.35$-0.28$-0.31$-0.26
High Forecast$0.50$0.41$0.28$0.17$-0.03$-0.09$-0.11$-0.11$-0.10$-0.29$-0.25$-0.17$-0.21$-0.27$-0.32$-0.36$-0.33$-0.37$-0.31$-0.36$-0.34$-0.42$-0.34$-0.35$-0.28$-0.31$-0.26
Low Forecast$0.37$0.30$0.21$0.13$-0.04$-0.12$-0.15$-0.23$-0.47$-0.39$-0.34$-0.23$-0.44$-0.36$-0.42$-0.49$-0.44$-0.37$-0.31$-0.36$-0.34$-0.42$-0.34$-0.35$-0.28$-0.31$-0.26
Surprise %---------------1.63%-5.38%-4.03%0.75%1.70%2.02%1.97%1.77%1.55%1.63%7.62%

According to 3 Wall Street analysts, Legend Biotech's projected average Quarter EPS for Mar 23 is $-0.42, with a low estimate of $-0.49 and a high estimate of $-0.36. This represents a -120.77% decrease compared to LEGN previous annual EPS of $2.01 (Dec 22).

Legend Biotech Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
LEGNLegend Biotech$34.68$89.60158.36%Buy
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
APLSApellis Pharmaceuticals$34.53$70.80105.04%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
DAWNDay One Biopharmaceuticals$12.64$24.0089.87%Buy
ZLABZai Lab$26.97$50.0085.39%Buy
PCVXVaxcyte$89.86$148.8065.59%Buy
AKROAkero Therapeutics$30.61$50.0063.35%Buy
ASNDAscendis Pharma$140.30$211.1450.49%Buy
ETNB89bio$7.98$12.0050.38%Buy
ACLXArcellx$82.03$111.6036.05%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy
TVTXTravere Therapeutics$17.14$21.7526.90%Buy
ALNYAlnylam Pharmaceuticals$246.58$310.6025.96%Buy
MDGLMadrigal Pharmaceuticals$306.08$315.753.16%Buy

LEGN Forecast FAQ

Is Legend Biotech a good buy?

Yes, according to 14 Wall Street analysts, Legend Biotech (LEGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 13 'Buy' recommendations, accounting for 92.86% of LEGN's total ratings.

What is LEGN's price target?

Legend Biotech (LEGN) average price target is $89.6 with a range of $83 to $94, implying a 163.37% from its last price of $34.02. The data is based on 14 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Legend Biotech stock go up soon?

According to Wall Street analysts' prediction for LEGN stock, the company can go up by 163.37% (from the last price of $34.02 to the average price target of $89.6), up by 176.31% based on the highest stock price target, and up by 143.97% based on the lowest stock price target.

Can Legend Biotech stock reach $50?

LEGN's average twelve months analyst stock price target of $89.6 supports the claim that Legend Biotech can reach $50 in the near future.

What are Legend Biotech's analysts' financial forecasts?

Legend Biotech's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.02B (high $1.15B, low $926.66M), average EBITDA is $-1.02B (high $-927M, low $-1.146B), average net income is $-82.359M (high $-62.314M, low $-98.233M), average SG&A $1.1B (high $1.23B, low $997.67M), and average EPS is $-0.451 (high $-0.341, low $-0.538). LEGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $1.66B (high $1.88B, low $1.5B), average EBITDA is $-1.659B (high $-1.498B, low $-1.881B), average net income is $211.71M (high $248.56M, low $184.94M), average SG&A $1.79B (high $2.03B, low $1.61B), and average EPS is $1.16 (high $1.36, low $1.01).

Did the LEGN's actual financial results beat the analysts' financial forecasts?

Based on Legend Biotech's last annual report (Dec 2022), the company's revenue was $117M, which missed the average analysts forecast of $123.3M by -5.11%. Apple's EBITDA was $-437M, beating the average prediction of $-123M by 254.77%. The company's net income was $-446M, beating the average estimation of $-258M by 72.72%. Apple's SG&A was $174.05M, beating the average forecast of $131.45M by 32.41%. Lastly, the company's EPS was $-2.81, beating the average prediction of $-1.415 by 98.56%. In terms of the last quarterly report (Mar 2023), Legend Biotech's revenue was $36.34M, missing the average analysts' forecast of $42.18M by -13.85%. The company's EBITDA was $-127M, beating the average prediction of $-42.177M by 200.78%. Legend Biotech's net income was $-112M, beating the average estimation of $-76.227M by 47.06%. The company's SG&A was $40.16M, missing the average forecast of $45.41M by -11.56%. Lastly, the company's EPS was $-0.68, beating the average prediction of $-0.417 by 62.89%